EMA's CHMP recommends approval of six new drugs

19 May 2017
ema_big

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued positive recommendations for six new medicines at its May meeting.

Among these, the CHMP recommended granting a marketing authorization for privately-held Italian drugmaker Dompé farmaceutici’s Oxervate (cenegermin) for the treatment of moderate to severe neurotrophic keratitis, a rare eye disease that can lead to loss of sight.

There is currently no satisfactory treatment for neurotrophic keratitis. Depending on the stage of their disease, patients may be given eye drops to moisten the eye, antibiotics for eye infections, and protective contact lenses, the CHMP noted. Where appropriate, they may undergo surgery. Oxervate has an orphan designation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical